3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
6
Pancreatic Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Appendiceal Neoplasms
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Referral and Consultation
×
Gastrointestinal
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts